Kynurenines in the mammalian brain: when physiology meets pathology (original) (raw)

• Liebig, J. Über Kynurensäure. Justus Liebigs Ann. Chem. 86, 125–126 (1853).
  Article Google Scholar
• Leklem, J. E. Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am. J. Clin. Nutr. 24, 659–672 (1971).
  Article CAS PubMed Google Scholar
• Perkins, M. N. & Stone, T. W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247, 184–187 (1982). This paper introduces the opposing effects of QUIN and KYNA as agonist and antagonist, respectively, of glutamate receptors.
  Article CAS PubMed Google Scholar
• Parsons, C. G. et al. Novel systemically active antagonists of the glycine site of the _N_-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 283, 1264–1275 (1997).
  CAS PubMed Google Scholar
• Maj, J., Rogoz, Z., Skuza, G. & Kolodziejczyk, K. Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5,7- dichloro-kynurenic acid, glycine site antagonists. Pol. J. Pharmacol. 46, 115–124 (1994).
  CAS PubMed Google Scholar
• Birch, P. J., Grossman, C. J. & Hayes, A. G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 154, 85–87 (1988).
  Article CAS PubMed Google Scholar
• Russi, P. et al. Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem. 59, 2076–2080 (1992).
  Article CAS PubMed Google Scholar
• Hilmas, C. et al. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21, 7463–7473 (2001). In this paper, the authors identify the α7nAChR as a new and preferential target of KYNA.
  Article CAS PubMed PubMed Central Google Scholar
• Grilli, M. et al. Modulation of the function of presynaptic α7 and non-α7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain. Br. J. Pharmacol. 149, 724–732 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, H. Q. et al. The astrocyte-derived α7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J. Mol. Neurosci. 40, 204–210 (2010).
  Article CAS PubMed Google Scholar
• Stone, T. W. Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats. Eur. J. Neurosci. 25, 2656–2665 (2007).
  Article PubMed Google Scholar
• Wang, J. et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281, 22021–22028 (2006).
  Article CAS PubMed Google Scholar
• DiNatale, B. C. et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 115, 89–97 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Moroni, F., Cozzi, A., Sili, M. & Mannaioni, G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J. Neural Transm. 119, 133–139 (2012).
  Article CAS PubMed Google Scholar
• Mok, M. H., Fricker, A. C., Weil, A. & Kew, J. N. Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 57, 242–249 (2009).
  Article CAS PubMed Google Scholar
• Lopes, C. et al. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at α7* nicotinic receptors. J. Pharmacol. Exp. Ther. 322, 48–58 (2007).
  Article CAS PubMed Google Scholar
• Hardeland, R. et al. Indole-3-pyruvic and -propionic acids, kynurenic acid, and related metabolites as luminophores and free-radical scavengers. Adv. Exp. Med. Biol. 467, 389–395 (1999).
  Article CAS PubMed Google Scholar
• Lugo-Huitron, R. et al. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol. Teratol. 33, 538–547 (2011).
  Article CAS PubMed Google Scholar
• Stone, T. W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45, 310–379 (1993).
  Google Scholar
• Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197–203 (2011).
  Article CAS PubMed Google Scholar
• Copeland, C. S., Neale, S. A. & Salt, T. E. Actions of xanthurenic acid, a putative endogenous group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus. Neuropharmacology, 2 Apr 2012 (doi: 10.1016/j.neuropharm.2012.03.009).
  Article CAS PubMed Google Scholar
• Fazio, F. et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol. Pharmacol. 81, 643–656 (2012).
  Article CAS PubMed Google Scholar
• Giles, G. I., Collins, C. A., Stone, T. W. & Jacob, C. Electrochemical and in vitro evaluation of the redox-properties of kynurenine species. Biochem. Biophys. Res. Commun. 300, 719–724 (2003).
  Article CAS PubMed Google Scholar
• Goldstein, L. E. et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote α-crystallin cross-linking by metal ion reduction. Biochemistry 39, 7266–7275 (2000).
  Article CAS PubMed Google Scholar
• Christen, S., Peterhans, E. & Stocker, R. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc. Natl Acad. Sci. USA 87, 2506–2510 (1990). Key paper linking metabolites of the kynurenine pathway to redox processes and inflammatory conditions.
  Article CAS PubMed PubMed Central Google Scholar
• Lapin, I. P. Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J. Neural Transm. 42, 37–43 (1978).
  Article CAS PubMed Google Scholar
• Stone, T. W. & Perkins, M. N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 72, 411–412 (1981).
  Article CAS PubMed Google Scholar
• de Carvalho, L. P., Bochet, P. & Rossier, J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunit. Neurochem. Int. 28, 445–452 (1996).
  Article CAS PubMed Google Scholar
• Ríos, C. & Santamaría, A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 16, 1139–1143 (1991).
  Article PubMed Google Scholar
• Stípek, S., Stastný, F., Pláteník, J., Crkovská, J. & Zima, T. The effect of quinolinate on rat brain lipid peroxidation is dependent on iron. Neurochem. Int. 30, 233–237 (1997).
  Article PubMed Google Scholar
• Pláteník, J., Stopka, P., Vejrazka, M. & Stípek, S. Quinolinic acid–iron (II) complexes: slow autoxidation, but enhanced hydroxyl radical production in the fenton reaction. Free Radic. Res. 34, 445–459 (2001).
  Article PubMed Google Scholar
• St'astny, F., Hinoi, E., Ogita, K. & Yoneda, Y. Ferrous iron modulates quinolinate-mediated [3H]MK-801 binding to rat brain synaptic membranes in the presence of glycine and spermidine. Neurosci. Lett. 262, 105–108 (1999).
  Article CAS PubMed Google Scholar
• Baran, H. & Schwarcz, R. Presence of 3-hydroxyanthranilic acid in rat tissues and evidence for its production from anthranilic acid in the brain. J. Neurochem. 55, 738–744 (1990).
  Article CAS PubMed Google Scholar
• Guidetti, P., Walsh, J. L. & Schwarcz, R. A fluorimetric assay for the determination of anthranilic acid in biological materials. Anal. Biochem. 220, 181–184 (1994).
  Article CAS PubMed Google Scholar
• Gobaille, S. et al. Xanthurenic acid distribution, transport, accumulation and release in the rat brain. J. Neurochem. 105, 982–993 (2008).
  Article CAS PubMed Google Scholar
• Moroni, F., Russi, P., Lombardi, G., Beni, M. & Carlá, V. Presence of kynurenic acid in the mammalian brain. J. Neurochem. 51, 177–180 (1988).
  Article CAS PubMed Google Scholar
• Saito, K., Markey, S. P. & Heyes, M. P. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience 51, 25–39 (1992).
  Article CAS PubMed Google Scholar
• Smythe, G. A. et al. ECNI GC-MS analysis of picolinic and quinolinic acids and their amides in human plasma, CSF, and brain tissue. Adv. Exp. Med. Biol. 527, 705–712 (2003).
  Article CAS PubMed Google Scholar
• Turski, W. A. et al. Identification and quantification of kynurenic acid in human brain tissue. Brain Res. 454, 164–169 (1988).
  Article CAS PubMed Google Scholar
• Dang, Y., Dale, W. E. & Brown, O. R. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic. Biol. Med. 28, 615–624 (2000).
  Article CAS PubMed Google Scholar
• Gál, E. M. & Sherman, A. D. L-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 5, 223–239 (1980).
  Article PubMed Google Scholar
• Speciale, C. & Schwarcz, R. Uptake of kynurenine into rat brain slices. J. Neurochem. 54, 156–163 (1990).
  Article CAS PubMed Google Scholar
• Guidetti, P., Eastman, C. L. & Schwarcz, R. Metabolism of [5-3H]kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway. J. Neurochem. 65, 2621–2632 (1995).
  Article CAS PubMed Google Scholar
• Guillemin, G. J. et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78, 842–853 (2001).
  Article CAS PubMed Google Scholar
• Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y. & Smith, Q. R. Blood–brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56, 2007–2017 (1991).
  Article CAS PubMed Google Scholar
• Speciale, C., Ungerstedt, U. & Schwarcz, R. Production of extracellular quinolinic acid in the striatum studied by microdialysis in unanesthetized rats. Neurosci. Lett. 104, 345–350 (1989).
  Article CAS PubMed Google Scholar
• Speciale, C. et al. Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid. Neurosci. Lett. 116, 198–203 (1990).
  Article CAS PubMed Google Scholar
• Speciale, C. & Schwarcz, R. On the production and disposition of quinolinic acid in rat brain and liver slices. J. Neurochem. 60, 212–218 (1993).
  Article CAS PubMed Google Scholar
• Gramsbergen, J. B. et al. Brain-specific modulation of kynurenic acid synthesis in the rat. J. Neurochem. 69, 290–298 (1997).
  Article CAS PubMed Google Scholar
• Hodgkins, P. S. & Schwarcz, R. Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate. Eur. J. Neurosci. 10, 1986–1994 (1998).
  Article CAS PubMed Google Scholar
• Hodgkins, P. S., Wu, H. Q., Zielke, H. R. & Schwarcz, R. 2-Oxoacids regulate kynurenic acid production in the rat brain: studies in vitro and in vivo. J. Neurochem. 72, 643–651 (1999).
  Article CAS PubMed Google Scholar
• Rassoulpour, A., Wu, H.-Q., Poeggeler, B. & Schwarcz, R. Systemic D-amphetamine administration causes a reduction of kynurenic acid levels in rat brain. Brain Res. 802, 111–118 (1998).
  Article CAS PubMed Google Scholar
• Uwai, Y., Honjo, H. & Iwamoto, K. Interaction and transport of kynurenic acid via human organic anion transporters hOAT1 and hOAT3. Pharmacol. Res. 65, 254–260 (2012).
  Article CAS PubMed Google Scholar
• Foster, A. C., Miller, L. P., Oldendorf, W. H. & Schwarcz, R. Studies on the disposition of quinolinic acid after intracerebral or systemic administration in the rat. Exp. Neurol. 84, 428–440 (1984).
  Article CAS PubMed Google Scholar
• Salter, M. & Pogson, C. I. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Biochem. J. 229, 499–504 (1985).
  Article CAS PubMed PubMed Central Google Scholar
• Espey, M. G. & Namboodiri, M. A. A. Selective metabolism of kynurenine in the spleen in the absence of indoleamine 2,3-dioxygenase induction. Immunol. Lett. 71, 67–72 (2000).
  Article CAS PubMed Google Scholar
• Belladonna, M. L. et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 177, 130–137 (2006).
  Article CAS PubMed Google Scholar
• Huang, L., Baban, B., Johnson, B. A. 3rd & Mellor, A. L. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int. Rev. Immunol. 29, 133–155 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Saito, K. et al. Kynurenine pathway enzymes in brain: respones to ischemic brain injury versus systemic immune activation. J. Neurochem. 61, 2061–2070 (1993).
  Article CAS PubMed Google Scholar
• Schwarcz, R. & Pellicciari, R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 303, 1–10 (2002).
  Article CAS PubMed Google Scholar
• Guillemin, G. J. et al. Characterization of the kynurenine pathway in human neurons. J. Neurosci. 27, 12884–12892 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, P. et al. Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol. Cell. Biol. 24, 6919–6930 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Carpenedo, R. et al. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 13, 2141–2147 (2001).
  Article CAS PubMed Google Scholar
• Rassoulpour, A., Wu, H. Q., Ferré, S. & Schwarcz, R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 93, 762–765 (2005).
  Article CAS PubMed Google Scholar
• Amori, L. et al. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 159, 196–203 (2009).
  Article CAS PubMed Google Scholar
• Zmarowski, A. et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur. J. Neurosci. 29, 529–538 (2009).
  Article CAS PubMed Google Scholar
• Albuquerque, E. X., Pereira, E. F., Alkondon, M. & Rogers, S. W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 89, 73–120 (2009).
  Article CAS PubMed Google Scholar
• Shepard, P. D., Joy, B., Clerkin, L. & Schwarcz, R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28, 1454–1462 (2003).
  Article CAS PubMed Google Scholar
• Erhardt, S., Schwieler, L., Emanuelsson, C. & Geyer, M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol. Psychiatry 56, 255–260 (2004).
  Article CAS PubMed Google Scholar
• Chess, A. C., Simoni, M. K., Alling, T. E. & Bucci, D. J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 33, 797–804 (2007).
  Article PubMed Google Scholar
• Chess, A. C., Landers, A. M. & Bucci, D. J. L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav. Brain Res. 201, 325–331 (2009).
  Article CAS PubMed Google Scholar
• Linderholm, K. R. et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology 53, 918–924 (2007).
  Article CAS PubMed Google Scholar
• Erhardt, S., Oberg, H., Mathe, J. M. & Engberg, G. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20, 353–362 (2001).
  Article CAS Google Scholar
• Potter, M. C. et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35, 1734–1742 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Pocivavsek, A. et al. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 36, 2357–2367 (2011). This article is the first to demonstrate that acute upregulation of endogenous KYNA levels worsens, whereas acute downregulation ameliorates, cognitive function.
  Article CAS PubMed PubMed Central Google Scholar
• Giorgini, F. et al. Generation and initial characterization of homozygous and heterozygous kynurenine 3-monooxygenase knockout mice. Soc. Neurosci. Abstr. 466.01 (Washington, DC, 12–16 Nov 2011).
• Baban, B. et al. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61, 67–77 (2004).
  Article CAS PubMed Google Scholar
• Kanai, M. et al. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol. Brain 2, 8 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Schwarcz, R., Whetsell, W. O. Jr & Mangano, R. M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316–318 (1983).
  Article CAS PubMed Google Scholar
• Foster, A. C., Vezzani, A., French, E. D. & Schwarcz, R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48, 273–278 (1984). In this report, the authors describe the excitotoxic effect of QUIN and the distinct neuroprotective properties of KYNA, suggesting a role for both of these metabolites in the pathophysiology of neurodegenerative diseases and seizure disorders.
  Article CAS PubMed Google Scholar
• Simon, R. P., Swan, J. H., Griffiths, T. & Meldrum, B. S. Blockade of _N_-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226, 850–852 (1984).
  Article CAS PubMed Google Scholar
• Wieloch, T. Hypoglycemia-induced neuronal damage prevented by an _N_-methyl-D-aspartate antagonist. Science 230, 681–683 (1985).
  Article CAS PubMed Google Scholar
• Schwarcz, R., Foster, A. C., French, E. D., Whetsell, W. O. Jr & Köhler, C. Excitotoxic models for neurodegenerative disorders. Life Sci. 35, 19–32 (1984).
  Article CAS PubMed Google Scholar
• Coyle, J. T. & Schwarcz, R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263, 244–246 (1976).
  Article CAS PubMed Google Scholar
• Guidetti, P., Luthi-Carter, R. E., Augood, S. J. & Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17, 455–461 (2004).
  Article CAS PubMed Google Scholar
• Tai, Y. F. et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130, 1759–1766 (2007).
  Article PubMed Google Scholar
• Whetsell, W. O. Jr & Schwarcz, R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci. Lett. 97, 271–275 (1989).
  Article CAS PubMed Google Scholar
• Kerr, S. J., Armati, P. J., Guillemin, G. J. & Brew, B. J. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12, 355–363 (1998).
  Article CAS PubMed Google Scholar
• Pearson, S. J. & Reynolds, G. P. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci. Lett. 144, 199–201 (1992).
  Article CAS PubMed Google Scholar
• Okuda, S., Nishiyama, N., Saito, H. & Katsuki, H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 70, 299–307 (1998).
  Article CAS PubMed Google Scholar
• Guidetti, P. & Schwarcz, R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11, 3857–3863 (1999).
  Article CAS PubMed Google Scholar
• Chiarugi, A., Meli, E. & Moroni, F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 77, 1310–1318 (2001).
  Article CAS PubMed Google Scholar
• Beal, M. F. et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 108, 80–87 (1992).
  Article CAS PubMed Google Scholar
• Sapko, M. T. et al. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp. Neurol. 197, 31–40 (2006).
  Article CAS PubMed Google Scholar
• Guidetti, P. et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 23, 190–197 (2006).
  Article CAS PubMed Google Scholar
• Guidetti, P., Reddy, P. H., Tagle, D. A. & Schwarcz, R. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci. Lett. 283, 233–235 (2000).
  Article CAS PubMed Google Scholar
• Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C. & Muchowski, P. J. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nature Genet. 37, 526–531 (2005).
  Article CAS PubMed Google Scholar
• Giorgini, F. et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J. Biol. Chem. 283, 7390–7400 (2008).
  Article CAS PubMed Google Scholar
• Campesan, S. et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 21, 961–966 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ogawa, T. et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42, 1702–1706 (1992).
  Article CAS PubMed Google Scholar
• Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O. & Cullen, K. M. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol. 31, 395–404 (2005).
  Article CAS PubMed Google Scholar
• Bonda, D. J. et al. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep. 15, 161–168 (2010).
  Article CAS PubMed Google Scholar
• Rahman, A. et al. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS ONE 4, e6344 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Baran, H., Gramer, M., Honack, D. & Löscher, W. Systemic administration of kainate induces marked increases of endogenous kynurenic acid in various brain regions and plasma of rats. Eur. J. Pharmacol. 286, 167–175 (1995).
  Article CAS PubMed Google Scholar
• Lehrmann, E. et al. Glial activation precedes seizures and hippocampal neurodegeneration in measles virus-infected mice. Epilepsia 49 (Suppl. 2), 13–23 (2008).
  Article PubMed Google Scholar
• Wu, H. Q. & Schwarcz, R. Seizure activity causes elevation of endogenous extracellular kynurenic acid in the rat brain. Brain Res. Bull. 39, 155–162 (1996).
  Article CAS PubMed Google Scholar
• Chugani, D. C. α-methyl-L-tryptophan: mechanisms for tracer localization of epileptogenic brain regions. Biomark. Med. 5, 567–575 (2011).
  Article CAS PubMed Google Scholar
• Heyes, M. P., Papagapiou, M., Leonard, C., Markey, S. P. & Auer, R. N. Effects of profound insulin-induced hypoglycemia on quinolinic acid in hippocampus and plasma. Adv. Exp. Med. Biol. 294, 679–682 (1991).
  Article CAS PubMed Google Scholar
• Saito, K., Nowak, T. S. J., Markey, S. P. & Heyes, M. P. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J. Neurochem. 60, 180–192 (1993).
  Article CAS PubMed Google Scholar
• Ceresoli-Borroni, G. & Schwarcz, R. Neonatal asphyxia in rats: acute effects on cerebral kynurenine metabolism. Pediatr. Res. 50, 231–235 (2001).
  Article CAS PubMed Google Scholar
• Blight, A. R., Saito, K. & Heyes, M. P. Increased levels of the excitotoxin quinolinic acid in spinal cord following contusion injury. Brain Res. 632, 314–316 (1993).
  Article CAS PubMed Google Scholar
• Moroni, F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmacol. 375, 87–100 (1999).
  Article CAS PubMed Google Scholar
• Németh, H., Toldi, J. & Vécsei, L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J. Neural Transm. 70, 285–304 (2006).
  Google Scholar
• Chen, Y. & Guillemin, G. J. Kynurenine pathway metabolites in humans: disease and healthy states. Int. J. Tryptophan Res. 2, 1–19 (2009).
  Article PubMed PubMed Central Google Scholar
• Miu, J., Ball, H. J., Mellor, A. L. & Hunt, N. H. Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria. Int. J. Parasitol. 39, 363–370 (2009).
  Article CAS PubMed Google Scholar
• Wang, Y. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nature Med. 16, 279–285 (2010).
  Article CAS PubMed Google Scholar
• Rodgers, J., Stone, T. W., Barrett, M. P., Bradley, B. & Kennedy, P. G. Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. Brain 132, 1259–1267 (2009).
  Article PubMed PubMed Central Google Scholar
• Perry, V. H., Nicoll, J. A. & Holmes, C. Microglia in neurodegenerative disease. Nature Rev. Neurol. 6, 193–201 (2010).
  Article Google Scholar
• Steinman, L. Elaborate interactions between the immune and nervous systems. Nature Immunol. 5, 575–581 (2004).
  Article CAS Google Scholar
• Guillemin, G. J., Smith, D. G., Smythe, G. A., Armati, P. J. & Brew, B. J. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv. Exp. Med. Biol. 527, 105–112 (2003).
  Article CAS PubMed Google Scholar
• Heyes, M. P. et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115, 1249–1273 (1992). This paper links inflammatory processes in the brain to a dysfunctional cerebral kynurenine pathway, suggesting that normalization of brain kynurenines may provide novel therapies for neurovirological and other neuroimmune diseases.
  Article PubMed Google Scholar
• Heyes, M. P., Mefford, I. N., Quearry, B. J., Dedhia, M. & Lackner, A. Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected rhesus macaques: relationship to clinical and viral status. Ann. Neurol. 27, 666–675 (1990).
  Article CAS PubMed Google Scholar
• Alberati-Giani, D., Ricciardi-Castagnoli, P., Köhler, C. & Cesura, A. M. Regulation of the kynurenine metabolic pathway by interferon-γ in murine clone macrophages and microglial cells. J. Neurochem. 66, 996–1004 (1996).
  Article CAS PubMed Google Scholar
• Lapin, I. P. Kynurenines as probable participants of depression. Pharmakopsychiatr. Neuropsychopharmakol. 6, 273–279 (1973).
  Article CAS PubMed Google Scholar
• Maes, M. et al. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci. 71, 1837–1848 (2002).
  Article CAS PubMed Google Scholar
• Capuron, L. et al. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol. Psychiatry 54, 906–914 (2003).
  Article CAS PubMed Google Scholar
• Raison, C. L. et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression. Mol. Psychiatry 15, 393–403 (2010).
  Article CAS PubMed Google Scholar
• O'Connor, J. C. et al. Interferon-γ and tumor necrosis factor-α mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guérin. J. Neurosci. 29, 4200–4209 (2009). In this paper, the authors demonstrate that the delayed emergence of depressive-like behaviour in mice is caused by the cytokine-induced induction of IDO.
  Article CAS PubMed PubMed Central Google Scholar
• O'Connor, J. C. et al. Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J. Immunol. 182, 3202–3212 (2009).
  Article CAS PubMed Google Scholar
• Smith, A. K. et al. Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol. Psychiatry 21 Jun 2011 (doi: 10.1038/mp.2011.67).
  Article CAS PubMed PubMed Central Google Scholar
• Manuelpillai, U. et al. Identification of kynurenine pathway enzyme mRNAs and metabolites in human placenta: up-regulation by inflammatory stimuli and with clinical infection. Am. J. Obstet. Gynecol. 192, 280–288 (2005).
  Article CAS PubMed Google Scholar
• Kohl, C. et al. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J. Affect. Disord. 86, 135–142 (2005).
  Article CAS PubMed Google Scholar
• Si, X., Miguel-Hidalgo, J. J., O'Dwyer, G., Stockmeier, C. A. & Rajkowska, G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 29, 2088–2096 (2004).
  Article CAS PubMed Google Scholar
• Czeh, B., Simon, M., Schmelting, B., Hiemke, C. & Fuchs, E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 31, 1616–1626 (2006).
  Article CAS PubMed Google Scholar
• Tynan, R. J. et al. Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain. Behav. Immun. 24, 1058–1068 (2010).
  Article CAS PubMed Google Scholar
• Steiner, J. et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflammation 8, 94 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hanson, N. D., Owens, M. J. & Nemeroff, C. B. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 36, 2589–2602 (2011).
  Article PubMed PubMed Central Google Scholar
• Zunszain, P. A. et al. Interleukin-1β: A new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37, 939–949 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Skolnick, P., Popik, P. & Trullas, R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 30, 563–569 (2009).
  Article CAS PubMed Google Scholar
• Laugeray, A. et al. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav. Brain Res. 210, 84–91 (2010).
  Article CAS PubMed Google Scholar
• Murrough, J. W., Iacoviello, B., Neumeister, A., Charney, D. S. & Iosifescu, D. V. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol. Learn. Mem. 96, 553–563 (2011).
  Article CAS PubMed Google Scholar
• Frazer, A., Pandey, G. N. & Mendels, J. Metabolism of tryptophan in depressive disease. Arch. Gen. Psychiatry 29, 528–535 (1973).
  Article CAS PubMed Google Scholar
• Krystal, J. H. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry 51, 199–214 (1994).
  Article CAS PubMed Google Scholar
• Lahti, A. C., Koffel, B., LaPorte, D. & Tamminga, C. A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9–19 (1995).
  Article CAS PubMed Google Scholar
• Anis, N. A., Berry, S. C., Burton, N. R. & Lodge, D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by _N_-methyl-aspartate. Br. J. Pharmacol. 79, 565–575 (1983).
  Article CAS PubMed PubMed Central Google Scholar
• Schwarcz, R. et al. Kynurenic acid: a potential pathogen in brain disorders. Ann. NY Acad. Sci. 648, 140–153 (1992).
  Article CAS PubMed Google Scholar
• Erhardt, S. et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313, 96–98 (2001).
  Article CAS PubMed Google Scholar
• Schwarcz, R. et al. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50, 521–530 (2001). This is the first direct evidence linking increased cerebral KYNA levels to the pathophysiology of schizophrenia.
  Article CAS PubMed Google Scholar
• Ceresoli-Borroni, G., Rassoulpour, A., Wu, H. Q., Guidetti, P. & Schwarcz, R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J. Neural Transm. 113, 1355–1365 (2006).
  Article CAS PubMed Google Scholar
• Sathyasaikumar, K. V. et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37, 1147–1156 (2011).
  Article PubMed Google Scholar
• Wonodi, I. et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry 68, 665–674 (2011).
  Article CAS PubMed Google Scholar
• Miller, C. L., Llenos, I. C., Dulay, J. R. & Weis, S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 1073–1074, 25–37 (2006).
• Miller, C. L. et al. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 15, 618–629 (2004).
  Article CAS PubMed Google Scholar
• Linderholm, K. R. et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 38, 426–432 (2010).
  Article PubMed PubMed Central Google Scholar
• Potvin, S. et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63, 801–808 (2008).
  Article CAS PubMed Google Scholar
• Müller, N. & Schwarz, M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 10, 131–148 (2006).
  Article PubMed Google Scholar
• Erhardt, S. & Engberg, G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol. Scand. 175, 45–53 (2002).
  Article CAS PubMed Google Scholar
• Goto, Y., Yang, C. R. & Otani, S. Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. Biol. Psychiatry 67, 199–207 (2010).
  Article PubMed Google Scholar
• Alexander, K. S., Wu, H. Q., Schwarcz, R. & Bruno, J. P. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the α7 positive modulator galantamine. Psychopharmacol. (Berl.) 220, 627–637 (2012).
  Article CAS Google Scholar
• Alexander, K. et al. Perinatal elevations of kynurenic acid dysregulate prefrontal glutamate release and produce set-shifting deficits in adults: a new model of schizophrenia. Soc. Neurosci. Abstr. 163.23 (Washington, DC, 12–16 Nov 2011).
• Trecartin, K. V. & Bucci, D. J. Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats. Schizophr. Res. 133, 156–158 (2011).
  Article PubMed PubMed Central Google Scholar
• Akagbosu, C. O., Evans, G. C., Gulick, D., Suckow, R. F. & Bucci, D. J. Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr. Bull. 20 Dec 2010 (doi: 10.1093/schbul/sbq151).
  Article PubMed PubMed Central Google Scholar
• Pocivavsek, A., Wu, H. Q., Elmer, G. I., Bruno, J. P. & Schwarcz, R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur. J. Neurosci. 35, 1605–1612 (2012).
  Article PubMed PubMed Central Google Scholar
• Aoyama, N. et al. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain Behav. 5, 364–368 (2006).
  Article CAS PubMed Google Scholar
• McFarlane, H. G. et al. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behav. 7, 152–163 (2008).
  Article CAS PubMed Google Scholar
• Justinova, Z. et al. Kynurenine 3-monooxygenase inhibition by Ro 61-8048 blocks self-administration of the psychoactive ingredient of marijuana in squirrel monkeys and prevents relapse. Soc. Neurosci. Abstr. 911.12 (Washington, DC, 12–16 Nov 2011).
• Olsson, S. K. et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 35, 195–199 (2010).
  Article PubMed PubMed Central Google Scholar
• Pellicciari, R. et al. Modulators of the kynurenine pathway of tryptophan metabolism. Synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem. 1, 528–531 (2006).
  Article CAS PubMed Google Scholar
• Chapin, D. S., Campbell, B., Strick, C. A. & Kozak, R. The impact of a KATII inhibitor on performance in the rat sustained attentional task (SAT) and conditioned avoidance responding (CAR). Soc. Neurosci. Abstr. 472.16 (San Diego, CA, 13–17 Nov 2010).
• Kozak, R. et al. A novel and systemically available KAT II inhibitor protects the α7 nicotinic acetylcholine receptor against blockade by kynurenic acid. Soc. Neurosci. Abstr. 767.30 (San Diego, CA, 13–17 Nov 2010).
• Abbott, A. et al. Inhibition of kynurenine aminotransferase ii (kat ii) protects against ketamine-induced cognitive impairment and improves spatial working memory. Soc. Neurosci. Abstr. 472.18 (San Diego, CA, 13–17 Nov 2010).
• Koshy Cherian, A. et al. A novel systemically-available kynurenine aminotransferase II (KATII) inhibitor normalizes prefrontal glutamatergic activity in an animal model of schizophrenia. Soc. Neurosci. Abstr. 568.13 (Washington, DC, 12–16 Nov 2011).
• Connick, J. H. et al. Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmacol. 23, 235–239 (1992).
  Article CAS PubMed Google Scholar
• Carpenedo, R. et al. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61, 237–244 (1994).
  Article CAS PubMed Google Scholar
• Speciale, C. et al. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur. J. Pharmacol. 315, 263–267 (1996).
  Article CAS PubMed Google Scholar
• Röver, S., Cesura, A. M., Huguenin, P., Kettler, R. & Szente, A. Synthesis and biochemical evaluation of _N_-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 40, 4378–4385 (1997).
  Article PubMed Google Scholar
• Cozzi, A., Carpenedo, R. & Moroni, F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (_m_-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxyl-[-N-4-(nitrophenyl)thiazol-2YL-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. _J. Cereb. Blood Flow Metab._ **19**, 771–777 (1999). **Using well-established animal models of cerebral ischaemia, this is the first paper to demonstrate impressive neuroprotection following systemic administration of a KMO inhibitor.**
  Article CAS PubMed Google Scholar
• Gregoire, L. et al. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res. 186, 161–167 (2008).
  Article CAS PubMed Google Scholar
• Clark, C. J. et al. Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect. Immun. 73, 5249–5251 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Zwilling, D. et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863–874 (2011). The authors show that relatively moderate, chronic peripheral KMO inhibition, by indirectly increasing brain KYNA formation, affords neuroprotection in animal models of Huntington's and Alzheimer's disease.
  Article CAS PubMed PubMed Central Google Scholar
• Owe-Young, R. et al. Kynurenine pathway metabolism in human blood–brain–barrier cells: implications for immune tolerance and neurotoxicity. J. Neurochem. 105, 1346–1357 (2008).
  Article CAS PubMed Google Scholar
• Chiarugi, A. & Moroni, F. Quinolinic acid formation in immune-activated mice: studies with (_m_-nitrobenzoyl)-alanine (_m_NBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl) thiazol-2yl]-benzenesulfonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology 38, 1225–1233 (1999).
  Article CAS PubMed Google Scholar
• Prendergast, G. C., Chang, M. Y., Mandik-Nayak, L., Metz, R. & Muller, A. J. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr. Med. Chem. 18, 2257–2262 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Combs, A. P. et al. 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase. US Patent Application #2012/0058079 (2012).
• Pilotte, L. et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl Acad. Sci. USA 109, 2497–2502 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sakurai, K., Zou, J.-P., Tschetter, J. R., Ward, J. M. & Shearer, G. M. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129, 186–196 (2002).
  Article CAS PubMed Google Scholar
• Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762–774 (2004).
  Article CAS Google Scholar
• Chiarugi, A. et al. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J. Neurochem. 65, 1176–1183 (1995).
  Article CAS PubMed Google Scholar
• Madge, D. J., Hazelwood, R., Iyer, R., Jones, H. T. & Salter, M. Novel tryptophan dioxygenase inhibitors and combined tryptophan dioxygenase/5-HT reuptake inhibitors. Bioorg. Med. Chem. Lett. 6, 857–860 (1996).
  Article CAS Google Scholar
• Parli, C. J., Krieter, P. & Schmidt, B. Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: a potent inhibitor of 3-hydroxyanthranilic acid oxidase. Arch. Biochem. Biophys. 203, 161–166 (1980).
  Article CAS PubMed Google Scholar
• Lehrmann, E., Molinari, A., Speciale, C. & Schwarcz, R. Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum. Exp. Brain Res. 141, 389–397 (2001).
  Article CAS PubMed Google Scholar
• Yates, J. R., Heyes, M. P. & Blight, A. R. 4-chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery, and preserves white matter after spinal cord injury. J. Neurotrauma 23, 866–881 (2006).
  Article PubMed Google Scholar
• Uemura, T. & Hirai, K. Kynurenine 3-monooxygenase activity of rat brain mitochondria determined by high performance liquid chromatography with electrochemical detection. Adv. Exp. Med. Biol. 294, 531–534 (1991).
  Article CAS PubMed Google Scholar
• Minakata, K., Fukushima, K., Nakamura, M. & Iwahashi, H. Effect of some naturally occurring iron ion chelators on the formation of radicals in the reaction mixtures of rat liver microsomes with ADP, Fe and NADPH. J. Clin. Biochem. Nutr. 49, 207–215 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ceresoli-Borroni, G., Guidetti, P., Amori, L., Pellicciari, R. & Schwarcz, R. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J. Neurosci. Res. 85, 845–854 (2007).
  Article CAS PubMed Google Scholar
• Oxenkrug, G. F. Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders. J. Neural Transm. 118, 75–85 (2011).
  Article CAS PubMed Google Scholar
• Thomas, S. R. & Stocker, R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep. 4, 199–220 (1999).
  Article CAS PubMed Google Scholar
• Ball, H. J., Yuasa, H. J., Austin, C. J., Weiser, S. & Hunt, N. H. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 41, 467–471 (2009).
  Article CAS PubMed Google Scholar
• Ren, S. & Correia, M. A. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase? Arch. Biochem. Biophys. 377, 195–203 (2000).
  Article CAS PubMed Google Scholar
• Han, Q., Cai, T., Tagle, D. A. & Li, J. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell. Mol. Life Sci. 67, 353–368 (2010).
  Article CAS PubMed Google Scholar
• Guidetti, P., Amori, L., Sapko, M. T., Okuno, E. & Schwarcz, R. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J. Neurochem. 102, 103–111 (2007).
  Article CAS PubMed Google Scholar
• Kawai, J., Okuno, E. & Kido, R. Organ distribution of rat kynureninase and changes of its activity during development. Enzyme 39, 181–189 (1988).
  Article CAS PubMed Google Scholar
• Foster, A. C., White, R. J. & Schwarcz, R. Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J. Neurochem. 47, 23–30 (1986).
  Article CAS PubMed Google Scholar
• Stachowski, E. & Schwarcz, R. Regulation of quinolinic acid neosynthesis in mouse, rat, and human brain by iron and iron chelation in vitro. J. Neural Transm. 119, 123–131 (2012).
  Article CAS PubMed Google Scholar
• Pucci, L., Perozzi, S., Cimadamore, F., Orsomando, G. & Raffaelli, N. Tissue expression and biochemical characterization of human 2-amino-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism. FEBS J. 274, 827–840 (2007).
  Article CAS PubMed Google Scholar
• Foster, A. C., Zinkand, W. C. & Schwarcz, R. Quinolinic acid phosphoribosyltransferase in rat brain. J. Neurochem. 44, 446–454 (1985).
  Article CAS PubMed Google Scholar
• Braidy, N., Guillemin, G. J. & Grant, R. Effects of kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons. Int. J. Tryptophan Res. 4, 29–37 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bellac, C. L., Coimbra, R. S., Christen, S. & Leib, S. L. Inhibition of the kynurenine-NAD+ pathway leads to energy failure and exacerbates apoptosis in pneumococcal meningitis. J. Neuropathol. Exp. Neurol. 69, 1096–1104 (2010).
  Article CAS PubMed Google Scholar
• Guillemin, G. J. et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep. 5, 108–111 (2000).
  Article CAS PubMed Google Scholar
• Guidetti, P., Hoffman, G. E., Melendez-Ferro, M., Albuquerque, E. X. & Schwarcz, R. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 55, 78–92 (2007).
  Article PubMed Google Scholar
• Heyes, M. P. et al. Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320, 595–597 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Liao, M. et al. Impaired dexamethasone-mediated induction of tryptophan 2,3-dioxygenase in heme-deficient rat hepatocytes: translational control by a hepatic eIF2α kinase, the heme-regulated inhibitor. J. Pharmacol. Exp. Ther. 323, 979–989 (2007).
  Article CAS PubMed Google Scholar
• Connor, T. J., Starr, N., O'Sullivan, J. B. & Harkin, A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-γ? Neurosci. Lett. 441, 29–34 (2008).
  Article CAS PubMed Google Scholar
• Cady, S. G. & Sono, M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291, 326–333 (1991).
  Article CAS PubMed Google Scholar
• Amori, L., Guidetti, P., Pellicciari, R., Kajii, Y. & Schwarcz, R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J. Neurochem. 109, 316–325 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Walsh, H. A., Leslie, P. L., O'Shea, K. C. & Botting, N. P. 2-Amino-4-[3′-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg. Med. Chem. Lett. 12, 361–363 (2002).
  Article CAS PubMed Google Scholar
• Luthman, J. Anticonvulsant effects of the 3-hydroxyanthranilic acid dioxygenase inhibitor NCR-631. Amino Acids 19, 325–334 (2000).
  Article CAS PubMed Google Scholar